- Home
- RMAX vs RNA Comparison
RMAX vs RNA Comparison
Compare RMAX & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMAX | RNA |
|---|---|---|
| Founded | 1973 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.9M | 222.5M |
| IPO Year | 2013 | 2025 |
Fundamental Metrics
Financial Performance| Metric | RMAX | RNA |
|---|---|---|
| Price | $12.36 | $13.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 20 |
| Target Price | $11.40 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 696.8K | 127.6K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $195,929,000.00 | N/A |
| Revenue This Year | $2.62 | $88.12 |
| Revenue Next Year | $1.24 | $18.11 |
| P/E Ratio | $20.60 | ★ N/A |
| Revenue Growth | ★ 11.13 | N/A |
| 52 Week Low | $5.46 | $11.13 |
| 52 Week High | $14.63 | $73.06 |
Technical Indicators
Market Signals| Indicator | RMAX | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.31 | 63.95 |
| Support Level | $8.95 | $12.72 |
| Resistance Level | N/A | $14.05 |
| Average True Range (ATR) | 0.89 | 0.51 |
| MACD | 0.17 | 0.14 |
| Stochastic Oscillator | 56.09 | 86.89 |
Price Performance
Historical ComparisonAbout RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.